Consumo de medicamentos en población adulta: influencia del autoconsumo

Objetivo El objetivo del estudio es conocer las características de la población que se asocian al consumo y autoconsumo de fármacos en Aragón. Diseño Estudio transversal a través de la Encuesta Nacional de Salud de 2006. Emplazamiento Comunidad autónoma de Aragón. Participantes Población adulta residente en Aragón. Mediciones principales Consumo y autoconsumo de fármacos, así como características sociodemográficas, de salud y de estilos de vida. Resultados El 65,1% de los adultos aragoneses habían consumido al menos un fármaco en las últimas 2 semanas, el 11,7% lo hizo sin receta médica. Se observó mayor consumo en las mujeres y en personas de mayor edad. El mal estado de salud percibido incrementaba de manera significativa el consumo de fármacos. Las personas con bajo nivel de estudios tenían mayor consumo, mientras que el autoconsumo fue más frecuente en el grupo de mayor nivel de estudios Conclusiones El consumo de fármacos en Aragón es elevado, así como la prevalencia de autoconsumo. Resulta de gran interés conocer el perfil de estos pacientes para poder realizar intervenciones dirigidas a reducir el consumo innecesario y mejorar la adecuación y seguridad de los fármacos utilizados Objective The objective of this study is to determine the factors associated with medicine consumption and self-consumption in Aragón (Spain) Design Cross-sectional study from the National Health Survey 2006. Setting Aragón (Spain). Participants Adult population in Aragón (Spain). Main measurements Medicine consumption and the type of consumption. Demographic, health and health style variables were also considered. Results At least one drug was taken by the 65.1% of the adults in Aragón during the previous two weeks. Of this group, 11.7% were self-medicated. A higher frequency of consumption was observed in females and older people, and in those with a poor self-perceived health. People with a low educational level took drugs more often, but self-consumption was more frequent in the group with a high educational level. Conclusions Medicine consumption and self-consumption in adults in Aragón is common. It is of great interest to know the consumption profile of these patients in order to develop specific interventions to reduce unnecessary consumption and to improve safety

The management of acute venous thromboembolism in clinical practice. Results from the European PREFER in VTE Registry

Venous thromboembolism (VTE) is a significant cause of morbidity and mortality in Europe. Data from real-world registries are necessary, as clinical trials do not represent the full spectrum of VTE patients seen in clinical practice. We aimed to document the epidemiology, management and outcomes of VTE using data from a large, observational database. PREFER in VTE was an international, non-interventional disease registry conducted between January 2013 and July 2015 in primary and secondary care across seven European countries. Consecutive patients with acute VTE were documented and followed up over 12 months. PREFER in VTE included 3,455 patients with a mean age of 60.8 ± 17.0 years. Overall, 53.0 % were male. The majority of patients were assessed in the hospital setting as inpatients or outpatients (78.5 %). The diagnosis was deep-vein thrombosis (DVT) in 59.5 % and pulmonary embolism (PE) in 40.5 %. The most common comorbidities were the various types of cardiovascular disease (excluding hypertension; 45.5 %), hypertension (42.3 %) and dyslipidaemia (21.1 %). Following the index VTE, a large proportion of patients received initial therapy with heparin (73.2 %), almost half received a vitamin K antagonist (48.7 %) and nearly a quarter received a DOAC (24.5 %). Almost a quarter of all presentations were for recurrent VTE, with >80 % of previous episodes having occurred more than 12 months prior to baseline. In conclusion, PREFER in VTE has provided contemporary insights into VTE patients and their real-world management, including their baseline characteristics, risk factors, disease history, symptoms and signs, initial therapy and outcomes

CMS physics technical design report : Addendum on high density QCD with heavy ions

Peer reviewe

Nurses' perceptions of aids and obstacles to the provision of optimal end of life care in ICU

Contains fulltext : 172380.pdf (publisher's version ) (Open Access

Vivero Centroamericano de adaptación y rendimiento: VICAR 1983-1984

Centro Internacional de Agricultura Tropical (CIAT)UCR::Vicerrectoría de Investigación::Unidades de Investigación::Ciencias Agroalimentarias::Estación Experimental Agrícola Fabio Baudrit Moreno (EEAFBM

Supplementary Material for: Cost of Hospitalizations due to Exacerbation in Patients with Non-Cystic Fibrosis Bronchiectasis

<b><i>Background:</i></b> Knowing the cost of hospitalizations for exacerbation in bronchiectasis patients is essential to perform cost-effectiveness studies of treatments that aim to reduce exacerbations in these patients. <b><i>Objectives:</i></b> To find out the mean cost of hospitalizations due to exacerbations in bronchiectasis patients, and to identify factors associated with higher costs. <b><i>Methods:</i></b> Prospective, observational, multicenter study in adult bronchiectasis patients hospitalized due to exacerbation. All expenses from the patients’ arrival at hospital to their discharge were calculated: diagnostic tests, treatments, transferals, home hospitalization, admission to convalescence centers, and hospitals’ structural costs for each patient (each hospital’s tariff for emergencies and 70% of the price of a bed for each day in a hospital ward). <b><i>Results:</i></b> A total of 222 patients (52.7% men, mean age 71.8 years) admitted to 29 hospitals were included. Adding together all the expenses, the mean cost of the hospitalization was EUR 5,284.7, most of which correspond to the hospital ward (86.9%), and particularly to the hospitals’ structural costs. The adjusted multivariate analysis showed that chronic bronchial infection by <i>Pseudomonas aeruginosa</i>, days spent in the hospital, and completing the treatment with home hospitalization were factors independently associated with a higher overall cost of the hospitalization. <b><i>Conclusions:</i></b> The mean cost of a hospitalization due to bronchiectasis exacerbation obtained from the individual data of each episode is higher than the cost per process calculated by the health authorities. The most determining factor of a higher cost is chronic bronchial infection due to <i>P. aeruginosa</i>, which leads to a longer hospital stay and the use of home hospitalization

The management of patients with venous thromboembolism in Italy: insights from the PREFER in VTE registry

Venous thromboembolism (VTE) is the third most common cardiovascular disease. Real-life data on the clinical presentation, risk factors, diagnosis, and treatment of VTE in Italy and Europe are required to optimize the management of this disease. The PREFER in VTE registry, a prospective non-interventional real-life study, was designed to assess clinical characteristics and management of patients with VTE, use of health care resources, and on-treatment patient quality of life. Eligible consecutive patients with objectively diagnosed VTE were enrolled in the registry and followed up for 12 months. Between January and December 2013, 816 Italian and 1027 patients from 6 European countries other than Italy (European patients) were enrolled in the registry, and followed up until December 2014. Italian patients were the oldest (mean age 65.7 years) among the European patients. The Italian patients with a history of cancer were 24.6 % of whom 63.2 % had an active cancer (18.2 and 57.0 %, respectively, in Europe). Parenteral heparin was given, as initial treatment, in 73.8 % of Italian patients (66.4 % in Europe); VKA in combination with other treatments in 45.8 % (34.7 % in Europe); and VKA as the only anticoagulant treatment in 24.4 % (17.2 % in Europe). Of the Italian patients, 43.2 and 90.6 % of patients were hospitalized for deep vein thrombosis and pulmonary embolism, respectively; 65.4 % were admitted to the hospital through the emergency department. Following a real world approach, PREFER in VTE shows that the Italian patients, among and compared to the European patients, are the oldest, have a history of cancer more commonly, receive an initial treatment with heparin more commonly, and are more commonly hospitalized, particularly if affected by PE